ETON - Eton Pharmaceuticals

-

$undefined

N/A

(N/A)

Eton Pharmaceuticals NasdaqGM:ETON Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Location: 21925 W. Field Parkway, Deer Park, IL, 60010-7278, United States | Website: https://www.etonpharma.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

520M

Cash

17.42M

Avg Qtr Burn

N/A

Short % of Float

2.84%

Insider Ownership

5.17%

Institutional Own.

53.05%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZONISADE (Zonisamide) (ET-104) Details
Rare genetic disease, Neurological disorder

Approved

Update

Approved

Quarterly sales

ALKINDI® SPRINKLE (hydrocortisone) Details
Adrenocortical Insufficiency (Pediatrics)

Approved

Quarterly sales

Carbaglu® (carglumic acid tablets) Details
Hyperammonemia NAGS deficient, chronic hyperammonemia

Approved

Quarterly sales

EPRONTIA (Topiramate Oral Solution) (ET-101) Details
Tonic-clonic seizures / seizures / migraine

Approved

Quarterly sales

Cysteine hydrochloride injection (generic - ANDA) Details
Additive to amino acid solutions to meet the nutritional requirements of newborn infants

Approved

Quarterly sales

Approved

Quarterly sales

KHINDIVI™ (hydrocortisone) Oral Solution Details
Pediatric Adrenocortical Insufficiency

Approved

Quarterly sales

Nitisinone Capsules Details
Tyrosinemia type 1, Rare diseases

Approved

Quarterly sales

Biorphen® (phenylephrine HCI) Details
Hypotension (vasodilation in the setting of anesthesia)

Approved

Quarterly sales

ET-600 Details
Diabetes insipidus

NDA

Acceptance for review

Failed

Discontinued

Lamotrigine Oral Suspension (ET-105) Details
Seizures, Epilepsy, Lennox-Gastaut syndrome

Failed

Discontinued